Literature DB >> 9660366

Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy.

L K Schrager1, M P D'Souza.   

Abstract

The eradication of human immunodeficiency virus 1 (HIV-1) from infected persons is the ultimate goal of HIV therapeutic interventions. Great strides have been made in developing potent antiretroviral regimens that greatly suppress HIV-1 replication. Despite these therapeutic advances, major obstacles remain to eradicating HIV-1. Reservoirs of HIV-1 have been identified that represent major impediments to eradication. Conceptually, there are 2 types of sanctuaries for HIV-1, cellular and anatomical. Cellular sanctuaries may include latent CD4+ T cells containing integrated HIV-1 provirus; macrophages, which may express HIV-1 for prolonged periods; and follicular dendritic cells, which may hold infectious HIV-1 on their surfaces for indeterminate lengths of time. The key anatomical reservoir for HIV-1 appears to be the central nervous system. An understanding of the nature of HIV within these reservoirs is critical to devising strategies to hasten viral eradication.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9660366     DOI: 10.1001/jama.280.1.67

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  78 in total

1.  Analysis of HIV-1 mutation patterns in patients failing antiretroviral therapy.

Authors:  E Quiros-Roldan; S Signorini; F Castelli; C Torti; A Patroni; M Airoldi; G Carosi
Journal:  J Clin Lab Anal       Date:  2001       Impact factor: 2.352

2.  Reservoirs for HIV-1.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-08       Impact factor: 3.725

3.  Genetic drift and within-host metapopulation dynamics of HIV-1 infection.

Authors:  S D Frost; M J Dumaurier; S Wain-Hobson; A J Brown
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-29       Impact factor: 11.205

4.  HIV-1 dynamics revisited: biphasic decay by cytotoxic T lymphocyte killing?

Authors:  R A Arnaout; M A Nowak; D Wodarz
Journal:  Proc Biol Sci       Date:  2000-07-07       Impact factor: 5.349

5.  Zinc finger protein designed to target 2-long terminal repeat junctions interferes with human immunodeficiency virus integration.

Authors:  Supachai Sakkhachornphop; Carlos F Barbas; Rassamee Keawvichit; Kanlaya Wongworapat; Chatchai Tayapiwatana
Journal:  Hum Gene Ther       Date:  2012-05-08       Impact factor: 5.695

6.  Antiretroviral release from poly(DL-lactide-co-glycolide) nanoparticles in mice.

Authors:  Christopher J Destache; Todd Belgum; Michael Goede; Annemarie Shibata; Michael A Belshan
Journal:  J Antimicrob Chemother       Date:  2010-08-21       Impact factor: 5.790

7.  Relationship of antiretroviral treatment to postmortem brain tissue viral load in human immunodeficiency virus-infected patients.

Authors:  Dianne Langford; Jennifer Marquie-Beck; Sergio de Almeida; Deborah Lazzaretto; Scott Letendre; Igor Grant; J Allen McCutchan; Eliezer Masliah; Ronald J Ellis
Journal:  J Neurovirol       Date:  2006-04       Impact factor: 2.643

8.  Independent evolution of human immunodeficiency virus (HIV) drug resistance mutations in diverse areas of the brain in HIV-infected patients, with and without dementia, on antiretroviral treatment.

Authors:  Theresa K Smit; Bruce J Brew; Wallace Tourtellotte; Susan Morgello; Benjamin B Gelman; Nitin K Saksena
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

9.  Compartmentalization of human immunodeficiency virus type 1 between blood monocytes and CD4+ T cells during infection.

Authors:  Jennifer A Fulcher; Yon Hwangbo; Rafael Zioni; David Nickle; Xudong Lin; Laura Heath; James I Mullins; Lawrence Corey; Tuofu Zhu
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

10.  Identification of a potential pharmacological sanctuary for HIV type 1 in a fraction of CD4(+) primary cells.

Authors:  Antonio Valentin; Matthew Morrow; Richard H Poirier; Karen Aleman; Richard Little; Robert Yarchoan; George N Pavlakis
Journal:  AIDS Res Hum Retroviruses       Date:  2010-01       Impact factor: 2.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.